HHS inspector general signs off on Novartis paying for pricey Kymriah
The Office of Inspector General (OIG) of HHS recently told Novartis that it can pay for low-income patients to access its $475,000 CAR-T therapy Kymriah …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
